A follow-up study of patients with juvenile idiopathic arthritis who discontinued etanercept due to disease remission

Assessment of the post-etanercept (ET) disease course in patients with juvenile idiopathic arthritis (JIA) who discontinued the drug due to disease remission, using a recently developed tool that scores the disease activity. Eleven patients (F/M 9/2, median age 9.2 years), with either a polyarthriti...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental rheumatology 2010-11, Vol.28 (6), p.919-922
Main Authors: PRATSIDOU-GERTSI, P, TRACHANA, M, PARDALOS, G, KANAKOUDI-TSAKALIDOU, F
Format: Article
Language:English
Subjects:
Antirheumatic Agents - therapeutic use
Arthritis, Juvenile - drug therapy
Arthritis, Juvenile - physiopathology
Biological and medical sciences
Child
Disability Evaluation
Diseases of the osteoarticular system
Etanercept
Female
Follow-Up Studies
Humans
Immunoglobulin G - therapeutic use
Immunomodulators
Inflammatory joint diseases
Male
Medical sciences
Pharmacology. Drug treatments
Receptors, Tumor Necrosis Factor - therapeutic use
Remission Induction
Severity of Illness Index
Treatment Outcome
Withholding Treatment
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Assessment of the post-etanercept (ET) disease course in patients with juvenile idiopathic arthritis (JIA) who discontinued the drug due to disease remission, using a recently developed tool that scores the disease activity. Eleven patients (F/M 9/2, median age 9.2 years), with either a polyarthritis' (9) or an oligoarthritis' (2) disease course were followed up for 12.25-27 months after ET withdrawal. The median treatment period under ET was 36 months. The Juvenile Arthritis Disease Activity Score (JADAS) was used to grade the JIA activity at the time of ET commencement, at discontinuation and at the time of the flare. All 11 patients flared during the follow-up period. Compared to the time of ET initiation, JADAS was significantly reduced at ET discontinuation as well as at the time of the flare (26.3 to 0 and to 9.5 respectively, p
ISSN:0392-856X
1593-098X